Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines

Virology

Volumn 444, Issue 1-2, 2013, Pages 1-11

  Vogt, Alexander ^a,b   Scull, Margaret A ^a   Friling, Tamar ^a   Horwitz, Joshua A ^a   Donovan, Bridget M ^a   Dorner, Marcus ^a   Gerold, Gisa ^a   Labitt, Rachael N ^a   Rice, Charles M ^a   Ploss, Alexander ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

HCV animal model; Hepatitis C virus; Innate immunity; Species tropism; Viral assembly; Viral entry

Indexed keywords

APOLIPOPROTEIN E; CD81 ANTIGEN; MICRORNA 122; OCCLUDIN; VIRUS RNA;

ANIMAL CELL; ARTICLE; CELL ENGINEERING; CELL IMMORTALIZATION; CELL LINE; CONTROLLED STUDY; EMBRYO; EMBRYO CELL; FIBROBLAST; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIFE CYCLE STAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; RNA REPLICATION; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSMISSION;

HCV ANIMAL MODEL; HEPATITIS C VIRUS; INNATE IMMUNITY; SPECIES TROPISM; VIRAL ASSEMBLY; VIRAL ENTRY;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; HEPACIVIRUS; HEPATOCYTES; HUMANS; MICE; VIRAL TROPISM; VIROLOGY; VIRUS REPLICATION;

ANIMALIA; HEPATITIS C VIRUS; MURINAE;

EID: 84882843221     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.05.036     Document Type: Article

References (70)

1. Agnello V., Abel G., Elfahal M., Knight G.B., Zhang Q.-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 1999, 96:12766-12771.
2. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyer S.P., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
3. Andrus L., Marukian S., Jones C.T., Catanese M.T., Sheahan T.P., Schoggins J.W., Barry W.T., Dustin L.B., Trehan K., Ploss A., Bhatia S.N., Rice C.M. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 2011, 54:1901-1912.
4. Balachandran S., Kim C.N., Yeh W.C., Mak T.W., Bhalla K., Barber G.N. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 1998, 17:6888-6902.
5. Bartenschlager R., Cosset F.L., Lohmann V. Hepatitis C virus replication cycle. J. Hepatol. 2010, 53:583-585.
6. Barth H., Schafer C., Adah M.I., Zhang F., Linhardt R.J., Toyoda H., Kinoshita-Toyoda A., Toida T., Van Kuppevelt T.H., Depla E., Von Weizsacker F., Blum H.E., Baumert T.F. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 2003, 278:41003-41012.
7. Blight K.J., McKeating J.A., Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 2002, 76:13001-13014.
8. Buehler E., Khan A.A., Marine S., Rajaram M., Bahl A., Burchard J., Ferrer M. siRNA off-target effects in genome-wide screens identify signaling pathway members. Sci. Rep. 2012, 2:428.
9. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012, 142:1279-1287. e1273.
10. Catanese M.T., Ansuini H., Graziani R., Huby T., Moreau M., Ball J.K., Paonessa G., Rice C.M., Cortese R., Vitelli A., Nicosia A. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 2010, 84:34-43.
11. Chang J., Nicolas E., Marks D., Sander C., Lerro A., Buendia M.A., Xu C., Mason W.S., Moloshok T., Bort R., Zaret K.S., Taylor J.M. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004, 1:106-113.
12. Chang K.S., Cai Z., Zhang C., Sen G.C., Williams B.R., Luo G. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J. Virol. 2006, 80:7364-7374.
13. Da Costa D., Turek M., Felmlee D.J., Girardi E., Pfeffer S., Long G., Bartenschlager R., Zeisel M.B., Baumert T.F. Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells. J. Virol 2012.
14. Da Costa D., Turek M., Felmlee D.J., Girardi E., Pfeffer S., Long G., Bartenschlager R., Zeisel M.B., Baumert T.F. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J. Virol. 2012, 86:11919-11925.
15. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., Jones C.T., Schoggins J.W., Catanese M.T., Burton D.R., Law M., Rice C.M., Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
16. Dorner M., Rice C.M., Ploss A. Study of hepatitis C virus entry in genetically humanized mice. Methods 2012.
17. Durbin J.E., Hackenmiller R., Simon M.C., Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84:443-450.
18. Dustin L.B., Rice C.M. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 2007, 25:71-99.
19. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
20. Flint M., von Hahn T., Zhang J., Farquhar M., Jones C.T., Balfe P., Rice C.M., McKeating J.A. Diverse CD81 proteins support hepatitis C virus infection. J. Virol. 2006, 80:11331-11342.
21. Frentzen A., Huging K., Bitzegeio J., Friesland M., Haid S., Gentzsch J., Hoffmann M., Lindemann D., Zimmer G., Zielecki F., Weber F., Steinmann E., Pietschmann T. Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines. PLoS Pathog. 2011, 7:e1002029.
22. Henke J.I., Goergen D., Zheng J., Song Y., Schuttler C.G., Fehr C., Junemann C., Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008, 27:3300-3310.
23. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
24. Horwitz J.A., Dorner M., Friling T., Donovan B.M., Vogt A., Loureiro J., Oh T., Rice C.M., Ploss A. Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein. Virology 2013.
25. Jopling C.L., Schutz S., Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008, 4:77-85.
26. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
27. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
28. Kimura T., Kadokawa Y., Harada H., Matsumoto M., Sato M., Kashiwazaki Y., Tarutani M., Tan R.S., Takasugi T., Matsuyama T., Mak T.W., Noguchi S., Taniguchi T. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1996, 1:115-124.
29. Kimura T., Nakayama K., Penninger J., Kitagawa M., Harada H., Matsuyama T., Tanaka N., Kamijo R., Vilcek J., Mak T.W., et al. Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 1994, 264:1921-1924.
30. Koutsoudakis G., Kaul A., Steinmann E., Kallis S., Lohmann V., Pietschmann T., Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 2006, 80:5308-5320.
31. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
32. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., Ray S.C., Gale M., Lemon S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adapter protein TRIF. Proc. Natl. Acad. Sci. USA 2005, 102:2992-2997.
33. Lin L.T., Noyce R.S., Pham T.N., Wilson J.A., Sisson G.R., Michalak T.I., Mossman K.L., Richardson C.D. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J. Virol. 2010, 84:9170-9180.
34. Lin L.T., Noyce R.S., Pham T.N., Wilson J.A., Sisson G.R., Michalak T.I., Mossman K.L., Richardson C.D. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J. Virol. 2010, 84:9170-9180.
35. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
36. Liu S., Yang W., Shen L., Turner J.R., Coyne C.B., Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009, 83:2011-2014.
37. Long G., Hiet M.S., Windisch M.P., Lee J.Y., Lohmann V., Bartenschlager R. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 2011.
38. Long G., Hiet M.S., Windisch M.P., Lee J.Y., Lohmann V., Bartenschlager R. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 2011, 141:1057-1066.
39. Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., McKeating J.A., Brino L., Baumert T.F. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011, 17:589-595.
40. Machlin E.S., Sarnow P., Sagan S.M. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc. Natl. Acad. Sci. USA 2011, 108:3193-3198.
41. Marine S., Bahl A., Ferrer M., Buehler E. Common seed analysis to identify off-target effects in siRNA screens. J. Biomol. Screening 2012, 17:370-378.
42. Marukian S., Andrus L., Sheahan T.P., Jones C.T., Charles E.D., Ploss A., Rice C.M., Dustin L.B. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology. 2011, 54:1913-1923.
43. Marukian S., Jones C.T., Andrus L., Evans M.J., Ritola K.D., Charles E.D., Rice C.M., Dustin L.B. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008, 48:1843-1850.
44. Matsuyama T., Kimura T., Kitagawa M., Pfeffer K., Kawakami T., Watanabe N., Kundig T.M., Amakawa R., Kishihara K., Wakeham A., et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993, 75:83-97.
45. McCaffrey A.P., Ohashi K., Meuse L., Shen S., Lancaster A.M., Lukavsky P.J., Sarnow P., Kay M.A. Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol. Ther. 2002, 5:676-684.
46. Meuleman P., Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 2008.
47. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
48. Molina S., Castet V., Fournier-Wirth C., Pichard-Garcia L., Avner R., Harats D., Roitelman J., Barbaras R., Graber P., Ghersa P., Smolarsky M., Funaro A., Malavasi F., Larrey D., Coste J., Fabre J.M., Sa-Cunha A., Maurel P. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 2007, 46:411-419.
49. Monazahian M., Bohme I., Bonk S., Koch A., Scholz C., Grethe S., Thomssen R. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 1999, 57:223-229.
50. Morikawa K., Lange C.M., Gouttenoire J., Meylan E., Brass V., Penin F., Moradpour D. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J. Viral. Hepat. 2011, 18:305-315.
51. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
52. Owen D.M., Huang H., Ye J., Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009, 394:99-108.
53. Patel M.R., Loo Y.M., Horner S.M., Gale M., Malik H.S. Convergent evolution of escape from hepaciviral antagonism in primates. PLoS Biol. 2012, 10:e1001282.
54. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., Abid K., Negro F., Dreux M., Cosset F.L., Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 2006, 103:7408-7413.
55. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
56. Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P., Rice C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-886.
57. Ploss A., Rice C.M. Towards a small animal model for hepatitis C. EMBO Rep. 2009.
58. Sainz B., Barretto N., Martin D.N., Hiraga N., Imamura M., Hussain S., Marsh K.A., Yu X., Chayama K., Alrefai W.A., Uprichard S.L. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 2012, 18:281-285.
59. Sandmann L., Ploss A. Barriers of hepatitis C virus interspecies transmission. Virology 2013, 435:70-80.
60. Sato M., Suemori H., Hata N., Asagiri M., Ogasawara K., Nakao K., Nakaya T., Katsuki M., Noguchi S., Tanaka N., Taniguchi T. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000, 13:539-548.
61. Satoh T., Kato H., Kumagai Y., Yoneyama M., Sato S., Matsushita K., Tsujimura T., Fujita T., Akira S., Takeuchi O. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc. Natl. Acad. Sci. USA 2010, 107:1512-1517.
62. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
63. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
64. Scull M.A., Ploss A. Exiting from uncharted territory: hepatitis C virus assembles in mouse cell lines. Hepatology 2012, 55:645-648.
65. Shcherbo D., Merzlyak E.M., Chepurnykh T.V., Fradkov A.F., Ermakova G.V., Solovieva E.A., Lukyanov K.A., Bogdanova E.A., Zaraisky A.G., Lukyanov S., Chudakov D.M. Bright far-red fluorescent protein for whole-body imaging. Nat. Methods 2007, 4:741-746.
66. Sumpter R., Loo Y.M., Foy E., Li K., Yoneyama M., Fujita T., Lemon S.M., Gale M. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 2005, 79:2689-2699.
67. Uprichard S.L., Chung J., Chisari F.V., Wakita T. Replication of a hepatitis C virus replicon clone in mouse cells. Virol. J. 2006, 3:89.
68. Walters K.A., Syder A.J., Lederer S.L., Diamond D.L., Paeper B., Rice C.M., Katze M.G. Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog. 2009, 5:e1000269.
69. Yang Y.L., Reis L.F., Pavlovic J., Aguzzi A., Schafer R., Kumar A., Williams B.R., Aguet M., Weissmann C. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 1995, 14:6095-6106.
70. Zhu Q., Guo J.T., Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J. Virol. 2003, 77:9204-9210.